

Olivier Dormond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5467260/publications.pdf>

Version: 2024-02-01

70
papers

3,451
citations

159585

30
h-index

149698

56
g-index

72
all docs

72
docs citations

72
times ranked

5900
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanotransduction, PROX1, and FOXC2 Cooperate to Control Connexin37 and Calcineurin during Lymphatic-Valve Formation. <i>Developmental Cell</i> , 2012, 22, 430-445.	7.0	339
2	NSAIDs inhibit $\alpha_5\beta_3$ integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. <i>Nature Medicine</i> , 2001, 7, 1041-1047.	30.7	273
3	PI3K and AKT: Unfaithful Partners in Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 21138-21152.	4.1	208
4	Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 41-49.	7.2	156
5	DLL4 promotes continuous adult intestinal lacteal regeneration and dietary fat transport. <i>Journal of Clinical Investigation</i> , 2015, 125, 4572-4586.	8.2	145
6	Prostaglandin E2 Promotes Integrin $\alpha_5\beta_3$ -dependent Endothelial Cell Adhesion, Rac-activation, and Spreading through cAMP/PKA-dependent Signaling. <i>Journal of Biological Chemistry</i> , 2002, 277, 45838-45846.	3.4	132
7	The Effects of mTOR-Akt Interactions on Anti-apoptotic Signaling in Vascular Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 23679-23686.	3.4	125
8	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
9	Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death. <i>Journal of Biological Chemistry</i> , 2003, 278, 43603-43614.	3.4	119
10	Tumor heterogeneity and cancer stem cell paradigm: Updates in concept, controversies and clinical relevance. <i>International Journal of Cancer</i> , 2015, 136, 1991-2000.	5.1	112
11	Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. <i>Angiogenesis</i> , 2015, 18, 233-244.	7.2	108
12	Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma. <i>Scientific Reports</i> , 2019, 9, 7103.	3.3	95
13	Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells. <i>EBioMedicine</i> , 2016, 4, 50-61.	6.1	89
14	Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. <i>Molecular Cancer</i> , 2010, 9, 57.	19.2	77
15	Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. <i>European Heart Journal</i> , 2010, 31, 67-76.	2.2	71
16	Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-10.	4.0	65
17	Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2004, 1654, 51-67.	7.4	62
18	Targeting renal cell carcinoma with NVP-BE2235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. <i>Molecular Cancer</i> , 2011, 10, 90.	19.2	60

#	ARTICLE	IF	CITATIONS
19	Calcineurin Inhibitors Activate the Proto-Oncogene Ras and Promote Protumorigenic Signals in Renal Cancer Cells. <i>Cancer Research</i> , 2009, 69, 8902-8909.	0.9	54
20	Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors. <i>Molecular Cancer</i> , 2016, 15, 78.	19.2	54
21	mTORC2 regulates PGE2-mediated endothelial cell survival and migration. <i>Biochemical and Biophysical Research Communications</i> , 2008, 372, 875-879.	2.1	53
22	Suppression of Tumor Angiogenesis Through the Inhibition of Integrin Function and Signaling in Endothelial Cells: Which Side to Target?. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2002, 9, 151-160.	1.7	52
23	Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. <i>Drug Resistance Updates</i> , 2001, 4, 314-321.	14.4	50
24	CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma. <i>Oncotarget</i> , 2019, 10, 7058-7070.	1.8	50
25	CD40-Induced Signaling in Human Endothelial Cells Results in mTORC2- and Akt-Dependent Expression of Vascular Endothelial Growth Factor In Vitro and In Vivo. <i>Journal of Immunology</i> , 2008, 181, 8088-8095.	0.8	45
26	Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives. <i>Cancers</i> , 2011, 3, 2478-2500.	3.7	44
27	Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A. <i>Thrombosis and Haemostasis</i> , 2003, 90, 577-585.	3.4	43
28	Manganese-induced integrin affinity maturation promotes recruitment of $\alpha_5\beta_3$ integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src. <i>Thrombosis and Haemostasis</i> , 2004, 92, 151-161.	3.4	42
29	Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy. <i>Cancers</i> , 2017, 9, 152.	3.7	41
30	Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. <i>BMC Cancer</i> , 2012, 12, 86.	2.6	39
31	PGE2-induced colon cancer growth is mediated by mTORC1. <i>Biochemical and Biophysical Research Communications</i> , 2014, 451, 587-591.	2.1	32
32	Drug-Eluting Beads Loaded with Antiangiogenic Agents for Chemoembolization: In Vitro Sunitinib Loading and Release and In Vivo Pharmacokinetics in an Animal Model. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 379-387.e2.	0.5	31
33	Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. <i>Radiology</i> , 2016, 280, 425-435.	7.3	30
34	Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies. <i>Oncotarget</i> , 2016, 7, 86026-86038.	1.8	30
35	Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors. <i>Oncotarget</i> , 2016, 7, 36666-36680.	1.8	25
36	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. <i>Cancers</i> , 2021, 13, 659.	3.7	25

#	ARTICLE	IF	CITATIONS
37	The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2011, 407, 714-719.	2.1	24
38	mTOR and Tumor Cachexia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2225.	4.1	24
39	Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin. <i>Anticancer Research</i> , 2010, 30, 799-804.	1.1	24
40	Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment. <i>Cancers</i> , 2021, 13, 1359.	3.7	21
41	Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1401.	4.1	20
42	mTOR – Understanding the Clinical Effects. <i>Transplantation Proceedings</i> , 2008, 40, S9-S12.	0.6	19
43	Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects. <i>Biochemical and Biophysical Research Communications</i> , 2013, 438, 32-37.	2.1	19
44	Targeting the intragraft microenvironment and the development of chronic allograft rejection. <i>Human Immunology</i> , 2012, 73, 1261-1268.	2.4	18
45	Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1222-F1230.	2.7	17
46	Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636037.	3.7	16
47	Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress. <i>Cancers</i> , 2019, 11, 1453.	3.7	15
48	Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study. <i>PLoS ONE</i> , 2017, 12, e0180437.	2.5	13
49	Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets. <i>Cancers</i> , 2021, 13, 2551.	3.7	12
50	Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6467.	4.1	12
51	Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3978.	3.7	12
52	Targeting the JNK Signaling Pathway Potentiates the Antiproliferative Efficacy of Rapamycin in LS174T Colon Cancer Cells. <i>Journal of Surgical Research</i> , 2011, 167, e193-e198.	1.6	11
53	Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment. <i>Cancers</i> , 2020, 12, 2697.	3.7	11
54	Systemic Buffers in Cancer Therapy: The Example of Sodium Bicarbonate; Stupid Idea or Wise Remedy?. , 2015, 5, .		10

#	ARTICLE	IF	CITATIONS
55	Tumor necrosis factor: clinical use and mechanisms of action. Drug Resistance Updates, 2000, 3, 271-276.	14.4	9
56	Suppression of Tumor Angiogenesis by Nonsteroidal Anti-Inflammatory Drugs: A New Function for Old Drugs. Scientific World Journal, The, 2001, 1, 808-811.	2.1	7
57	ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma. Biochemical Society Transactions, 2011, 39, 492-494.	3.4	7
58	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA. Hepatology Communications, 2021, 5, 1095-1105.	4.3	7
59	mTOR in Human Diseases. International Journal of Molecular Sciences, 2019, 20, 2351.	4.1	6
60	mTOR Inhibition and the Tumor Vasculature. Current Angiogenesis, 2012, 1, 11-19.	0.1	4
61	Thoracic Aortic Dilation/Aneurysm in Fabry Disease. American Journal of Medicine, 2013, 126, e23.	1.5	4
62	Correlation Between Portal Pressure and Indocyanine Green Retention Rate is Unaffected by the Cause of Cirrhosis: A Prospective Study. World Journal of Surgery, 2021, 45, 2546-2555.	1.6	3
63	Ascending aortic remodelling in Fabry disease after long-term enzyme replacement therapy. Swiss Medical Weekly, 2017, 147, w14517.	1.6	3
64	Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?. International Journal of Molecular Sciences, 2022, 23, 5343.	4.1	3
65	Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth. Biochemical and Biophysical Research Communications, 2019, 513, 546-552.	2.1	2
66	Images in Emergency Medicine. Annals of Emergency Medicine, 2005, 45, 586.	0.6	1
67	Hypermobility Ehlers-Danlos-like syndrome in Fabry disease. Clinical Genetics, 2019, 95, 627-628.	2.0	1
68	Invited commentary. Annals of Thoracic Surgery, 2006, 81, 1736-1737.	1.3	0
69	In vitro and in vivo evaluation of sunitinib eluting beads.. Journal of Clinical Oncology, 2013, 31, 246-246.	1.6	0
70	Evaluation of the antitumoral effect sunitinib eluting beads in VX2 liver tumour in a rabbit model.. Journal of Clinical Oncology, 2013, 31, 247-247.	1.6	0